Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (31-40 of 337) with videos related to

Pageof 34
Sort By:
BMC Health Services Research|July 15, 2020
Drug switching in the Netherlands: a cohort study of 20 active substancesPieter J Glerum, Marc Maliepaard, Vincent de Valk, et al.
Therapeutic Drug Monitoring|September 24, 2004
Therapeutic drug monitoring of nelfinavir in pregnancy: a case reportDavid M Burger, Karin J T Grintjes, Fred K Lotgering, et al.
Therapeutic Drug Monitoring|July 27, 2005
TDM: therapeutic drug measuring or therapeutic drug monitoring?Jacqueline A H Droste, Peter P Koopmans, Yechiel A Hekster, et al.
Antimicrobial Agents and Chemotherapy|September 10, 2014
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysisMichael J Dolton, Roger J M Brüggemann, David M Burger, et al.
Clinical Pharmacokinetics|April 11, 2022
Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIVLeena Zino, Jurjen S Kingma, Catia Marzolini, et al.
AIDS (London, England)|April 7, 2007
Atazanavir in plasma-exchange treatmentMilly E Attema-de Jonge, David M Burger, Eric J F Franssen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2015
Dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected childMaren I Blonk, Erik M van Maarseveen, Sibyl P M Geelen, et al.
AIDS (London, England)|December 21, 2022
Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case reportLeena Zino, Tom G Jacobs, Thomas Nieuwenstein, et al.
The Annals of Pharmacotherapy|March 28, 2003
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin useAlina S Bergshoeff, Tom F W Wolfs, Sibyl P M Geelen, et al.
Clinical Biochemistry|June 3, 2020
A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapyKarolien Dams, David M Burger, Jonas Weyler, et al.
Pageof 34

Showing results (31-40 of 337) with videos related to

Sort By:
Pageof 34
BMC Health Services Research|July 15, 2020
Drug switching in the Netherlands: a cohort study of 20 active substancesPieter J Glerum, Marc Maliepaard, Vincent de Valk, et al.
Therapeutic Drug Monitoring|September 24, 2004
Therapeutic drug monitoring of nelfinavir in pregnancy: a case reportDavid M Burger, Karin J T Grintjes, Fred K Lotgering, et al.
Therapeutic Drug Monitoring|July 27, 2005
TDM: therapeutic drug measuring or therapeutic drug monitoring?Jacqueline A H Droste, Peter P Koopmans, Yechiel A Hekster, et al.
Antimicrobial Agents and Chemotherapy|September 10, 2014
Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysisMichael J Dolton, Roger J M Brüggemann, David M Burger, et al.
Clinical Pharmacokinetics|April 11, 2022
Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIVLeena Zino, Jurjen S Kingma, Catia Marzolini, et al.
AIDS (London, England)|April 7, 2007
Atazanavir in plasma-exchange treatmentMilly E Attema-de Jonge, David M Burger, Eric J F Franssen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2015
Dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected childMaren I Blonk, Erik M van Maarseveen, Sibyl P M Geelen, et al.
AIDS (London, England)|December 21, 2022
Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case reportLeena Zino, Tom G Jacobs, Thomas Nieuwenstein, et al.
The Annals of Pharmacotherapy|March 28, 2003
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin useAlina S Bergshoeff, Tom F W Wolfs, Sibyl P M Geelen, et al.
Clinical Biochemistry|June 3, 2020
A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapyKarolien Dams, David M Burger, Jonas Weyler, et al.
Pageof 34